High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai
Find insight on Merck KGaA, IHH Healthcare and more in the latest Market Talks covering the health care sector.
The outlook lift comes on expectations of stronger momentum in the group’s life-sciences unit, resilience in healthcare, as well as its first-quarter performance and market conditions.
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
Elizabeth Schwartz will head up government relations at the for-profit hospital trade association as health systems brace for federal funding cuts.
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.